Choice Is Vital to Biosimilar Savings Picture

In a webinar this week, experts discussed the business dynamics that prevent providers from being able to choose the lowest-cost biosimilars. Several trastuzumab biosimilars have been launched this year, and 6 FDA-approved adalimumab biosimilars are lined up for...

Biosimilar uptake still limited in the U.S.

The European Medicines Agency approved the first biosimilar in Europe in 2006. It was almost 10 years before the United States followed. Despite potential savings for payers and patients, biosimilar uptake in the U.S. remains limited.

House Committee Calls for CMS Action on Biosimilars

The House Appropriations Committee has asked for policy action by CMS that will support access to, use of, and competition from lower-cost biosimilars to provide savings for seniors, patients, and taxpayers. The request came as the committee approved the fiscal year...